Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
1.155
+0.070
+6.45%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks! Unlock list
Mesoblast Ltd (MSB)
Sydney
| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| MSB | Sydney | AUD | Delayed | |
| MESO | NASDAQ | USD | Real-time | |
| MEOBF | OTC Markets | USD | Delayed |
Add to/Remove from a Portfolio
Add to Watchlist
- Volume: 17,254,229
- Bid/Ask: 1.150 / 1.155
- Day's Range: 1.113 - 1.200
Mesoblast
1.155
+0.070
+6.45%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Index Component
Mesoblast Ltd Company Profile
Get an in-depth profile of Mesoblast Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Contact Information
Address
55 Collins Street Level 38
Melbourne, 3000
Australia
Melbourne, 3000
Australia
Phone
61 3 9639 6036
Fax
61 3 9639 6030
Top Executives
| Name | Age | Since | Title |
|---|---|---|---|
| Joseph R. Swedish | 69 | 2018 | Independent Non-Executive Chairman |
| William A. M. Burns | 72 | 2014 | Independent Non-Executive Vice Chairman |
| Silviu Itescu | 64 | 2004 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director |
| Eric A. Rose | 71 | 2013 | Chief Medical Officer & Executive Director |
| Henry Krum | - | - | Member of Scientific Advisory Board |
| Robert M. Graham | - | - | Member of Scientific Advisory Board |
| Stephen Graves | - | - | Member of Scientific Advisory Board |
| Joseph M. Lane | - | - | Member of Scientific Advisory Board |
| Richard E. Gilbert | - | - | Member of Scientific Advisory Board |
| Philip James Facchina | 61 | 2021 | Independent Non-Executive Director |
| Philip R. Krause | - | 2022 | Non Executive Director |
| Jane Catherine Bell | - | 2022 | Independent Non-Executive Director |
Write your thoughts about Mesoblast Ltd
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Harry Aus
Feb 26, 2024 8:44
I'm retaining msb will have an approval this year buy
1
0
Umar Ohiko
Jan 22, 2022 0:50
i don't understand anything here
0
0
Wisdom Anyang
Jun 08, 2021 5:14
am new an in I don't understand anything here
0
0
NSingh
Oct 19, 2020 15:36
just buy
0
2
Full Time Full Time
Oct 19, 2020 9:48
what is the update for MSB? Buy, Hold or Sell?
0
0
Full Time Full Time
Oct 19, 2020 9:48
what is the update for MSB? Buy, Hold or Sell?
0
0
David E Youssef
Oct 05, 2020 16:44
Watch the sellout tomorrow
1
0
Poe Kae
Oct 02, 2020 22:02
in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
4
4
David E Youssef
Oct 02, 2020 22:02
It has been a on indicative sell for the lst few weeksAfter that hitThe indicators and MA will promote a further sellThere may be bullish rally due to the fact of how cheap it is since it hasnt dropped this low since 2016But that wont last long as there will be drastic pullback till they prove the product and build investor confident back up
3
1
Poe Kae
Oct 02, 2020 22:02
in my opinion msb will recover quite quickly from current share price. its a lot happening in US including th election. I would be worry if this is the only product they have inline but they have other products which are currently in stage 3 and some will soon be going for fda approval." be greedy when others are fearful " warren buffett
0
2
Asanka Asp
Oct 02, 2020 11:02
Buy or Sell?
0
2
Annie Weng
Oct 02, 2020 11:02
Buy
0
4
David E Youssef
Oct 02, 2020 11:02
Sell mate!It will take them a few months if that to prove the drug Coming close to the elections too
3
0
tu nguyen
Oct 02, 2020 11:02
if you think they have more ammo in the bank to prove themselves to the FDA - it's shopping time!
0
0
George SalmaS
Oct 02, 2020 11:02
Definitely sell, the sentiment is bearish. The share price will not bounce in the foreseeable future unless treatment efficacy is further substantiated & FDA approval is granted. There is a long way to go before this happens.
3
0
David E Youssef
Oct 02, 2020 11:02
George SalmaS totally agree, thats what i said. Absolute gamble if you buy, youre more likely to win against the casino than to make money on this share. A buy would be around the march low, $1 something
2
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review